Statistics
The Ovid Therapeutics stock price is currently $ 2.54 with a total market cap valuation of $ 479.38M (188.73M shares outstanding). The Ovid Therapeutics is trading on NASDAQ under the ticker sign OVID. Ovid Therapeutics price is up
You can buy Ovid Therapeutics (OVID) stock on eToro. For more information check our how to buy Ovid Therapeutics (OVID) stock guide.
Description
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Company Profile
- Full Name: Ovid Therapeutics
- Sector: Healthcare
- Website: https://www.ovidrx.com
